Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Calcium channel, voltage-dependent, L type, alpha 1C subunit (Cav1.2) is a critical transmembrane protein and voltage-gated ion channel. As the main alpha-1 subunit of L-type calcium channels in the adult heart, it forms the pore responsible for mediating the influx of calcium ions (Ca²⁺) into the cell upon membrane depolarization. The alpha-1 subunit consists of 24 transmembrane segments and forms a complex with alpha-2/delta and beta subunits in a 1:1:1 ratio. Its structure includes a voltage sensing domain (formed by S1-S4 segments) and a conduction pore (formed by S5-S6 segments), as well as gating apparatus. Cav1.2 plays crucial roles in signal transduction, membrane depolarization, action potential regulation, and particularly excitation-contraction coupling in cardiac, skeletal, and smooth muscle, as well as calcium-induced calcium release from endoplasmic reticulum stores. It is widely expressed in tissues including cardiac tissue, smooth muscle, neurons, pancreatic cells, and fibroblasts. Regulation involves voltage-dependent mechanisms, inhibition by STIM1, and binding of Ca²⁺/calmodulin to the C-terminus. Mutations in the gene encoding this subunit (CACNA1C) are associated with severe disorders like Timothy Syndrome (TS1, TS2) and Long QT Syndrome type 8 (LQT8), leading to cardiac arrhythmias and other developmental abnormalities. As a key ion channel, Cav1.2 is considered a therapeutic target, modulated by drugs such as dihydropyridines, which typically inhibit calcium influx by binding to the channel and affecting its gating kinetics.
Inhibition of calcium influx through binding to and inhibiting the channel. Modulation of channel gating kinetics. Drugs targeting this channel typically work by blocking calcium ion influx, which can reduce muscle contraction and electrical excitability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calcium channel, voltage-dependent, L type, alpha 1C subunit (Cav1.2).